Humana (NYSE:HUM) Given New $268.00 Price Target at Barclays

Humana (NYSE:HUM) had its price target trimmed by Barclays from $273.00 to $268.00 in a report released on Thursday morning,Benzinga reports. The brokerage currently has an equal weight rating on the insurance provider’s stock.

HUM has been the topic of a number of other reports. Robert W. Baird lifted their price objective on shares of Humana from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, April 15th. Truist Financial cut their price objective on shares of Humana from $325.00 to $305.00 and set a “hold” rating on the stock in a research note on Monday, May 12th. Raymond James upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price objective on the stock in a research note on Thursday, May 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $290.00 price target on shares of Humana in a research report on Thursday, May 1st. Sixteen equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $284.24.

Humana Stock Up 1.3%

Shares of NYSE:HUM opened at $234.68 on Thursday. The company has a market capitalization of $28.32 billion, a price-to-earnings ratio of 23.59, a price-to-earnings-growth ratio of 2.05 and a beta of 0.43. The company has a 50 day moving average of $251.34 and a two-hundred day moving average of $263.30. Humana has a 52-week low of $212.45 and a 52-week high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping analysts’ consensus estimates of $10.07 by $1.51. The firm had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The firm’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $7.23 earnings per share. As a group, analysts forecast that Humana will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.51%. Humana’s dividend payout ratio is currently 25.04%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. FPC Investment Advisory Inc. acquired a new position in Humana during the fourth quarter worth $27,000. Centricity Wealth Management LLC bought a new position in shares of Humana in the fourth quarter valued at about $30,000. Cary Street Partners Investment Advisory LLC grew its holdings in Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock worth $31,000 after acquiring an additional 46 shares during the last quarter. LFA Lugano Financial Advisors SA grew its holdings in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after acquiring an additional 45 shares during the last quarter. Finally, OFI Invest Asset Management bought a new stake in Humana during the 4th quarter worth about $33,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.